Mazdutide approved in US in 2025
2
100Ṁ37Dec 31
35%
chance
1H
6H
1D
1W
1M
ALL
Mazdutide, a dual GLP-1 and glucagon receptor agonist developed by Innovent Biologics and Eli Lilly, has shown promising results in weight management. It received approval from China's NMPA in June 2025. This market predicts whether the FDA will approve mazdutide for weight management in the U.S. before December 22, 2025. Resolution will be based on official FDA announcements.
This question is managed and resolved by Manifold.
Get 
1,000 to start trading!
1,000People are also trading
Related questions
Will Retatrutide (new obesity drug) be FDA approved by the end of 2026?
62% chance
💊Will INS018_055 be FDA-approved by 2030?
48% chance
Will one of the GLP agonist drugs (eg Semaglutude/Wegovy Tirzepatide/Mounjaro) have a black box warning by 2025
7% chance
Will Retatrutide (new obesity drug) be FDA approved by the end of 2025?
20% chance
Will Ozempic / semaglutide be FDA-approved for Alzheimer's before 2030?
62% chance
Will a drug to be used by most healthy adults be approved by 2043 year end?
70% chance
Will AOH1996 be FDA approved before 2040?
40% chance
Will 10 million Americans be on semaglutide (or yet-to-be-approved equally good or superior alternatives) by the end of 2030?
78% chance
When will retatrutide receive full FDA approval, making it legal to prescribe in the United States?
Will a drug that didn't go through human clinical trials be approved by 2034?
29% chance